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Background: There is a strong maternal parent-of-origin effect in determining susceptibility to multiple sclerosis
(MS). One hypothesis is that an abnormal intrauterine milieu leading to impaired fetal development could plausibly
also result in increased susceptibility to MS. A possible marker for this intrauterine insult is the presence of a non-
fatal congenital anomaly.
Methods: We investigated whether or not congenital anomalies are associated with MS in a population-based
cohort. We identified 7063 MS index cases and 2655 spousal controls with congenital anomaly information from
the Canadian Collaborative Project on Genetic Susceptibility to MS (CCPGSMS).
Results: The frequency of congential anomalies were compared between index cases and controls. No significant
differences were found.
Conclusions: Congenital anomalies thus do not appear to be associated with MS. However, we did not have
complete data on types and severity of congenital anomalies or on maternal birth history and thus this study
should be regarded as preliminary.
Background
Multiple sclerosis (MS) is an inflammatory disease of
the central nervous system (CNS) characterized by mye-
lin loss, varying degrees of axonal pathology and pro-
gressive neurological dysfunction [1]. Autoimmune
mechanisms are thought to have major roles in the
pathogenesis of MS [2] but the cause of the disease is
not yet conclusively understood [1]. A maternal parent-
of-origin effect in MS [3,4] has now been well demon-
strated but the biological basis underlying this remains
unknown [5].
Approximately 3% of babies born in North America
have a congenital anomaly [6]. A congenital anomaly is
an abnormality of structure, function or body metabo-
lism that is present at birth and results in physical or
mental disability, with varying degrees of severity [7].
Purely genetic factors (chromosomes, single gene muta-
tions) are believed to account for 15-25% of all congeni-
tal anomalies leaving up to 80% due to multifactorial
inheritance or environmental exposures [6]. These latter
two categories may be affected by factors such as fetal
exposures to infection (e.g. cytomegalovirus, varicella,
rubella), toxins (e.g. alcohol, cocaine, accutane) or
maternal medical conditions (diabetes, epilepsy, phe-
n y l k e t o n u r i a )[ 6 ] .I ti sp o s s i b l et h a tac o m p r o m i s e d
intrauterine environment underlies the maternal effect
seen in MS. One hypothesis is that an abnormal intrau-
terine milieu leading to impaired fetal development
could plausibly also result in increased susceptibility to
MS. A possible marker for this intrauterine insult is the
presence of a “non-fatal” congenital anomaly (hereafter
referred to simply as a “congenital anomaly”). If this
were true, one would expect an excess of congenital
anomalies in MS patients compared to gender and eth-
nicity-matched controls.
Methods
The population-based Canadian Collaborative Project on
Genetic Susceptibility to Multiple Sclerosis (CCPGSMS)
has been collecting perinatal data on MS index cases
and spousal controls using structured telephone inter-
views with appropriate consents [7]. Data specific for
the question of congenital anomalies were collected
from mothers of index cases and mothers of controls.
Each participating CCPGSMS site has obtained ethical
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The entire project was reviewed and approved by the
University of British Columbia in compliance with the
Helsinki Declaration.
Statistical analyses
The Chi squared test was used to assess significance
when comparing the frequency of congenital anomalies
in index cases and controls. The effect of congenital
anomalies and sex on the risk of MS was assessed by
logistic regression using the R statistical package.
Results
Maternal information on congenital anomalies could be
collected for 7063 MS index cases and 2655 spousal
controls. The clinical and demographic details of the
index cases and controls are shown in Table 1.
Two hundred and seventy (3.8%) MS index cases
reported a congenital anomaly, not significantly different
(p = 0.97) from controls (n = 101, 3.8%). As there is a
preponderance of females with MS [8], there is by defini-
tion a corresponding over-representation of male spousal
controls. If the trait of interest is sex-limited, then analy-
sis by sex stratified cases and controls is important [9].
When we compared male index cases and female con-
trols separately from male index case and male controls,
there were again no significant differences. Logistic
regression confirmed this showing an effect of female sex
on the risk of MS (p <1×1 0
-16) but no effect of having a
congenital abnormality (p = 0.92).
Discussion
Environmental risk factors are known to be responsible
for 8-12% of congenital anomalies and are a likely con-
tributing factor in an additional 20-25% of anomalies as
part of multifactorial inheritance [10,11] If the same risk
factors acting in utero contribute to both congenital
anomalies and future MS risk, then congenital anoma-
lies could be used as biomarkers for MS. The large MS
index case and control sample size used in this study
did not support this hypothesis. It may well be possible
that congenital anomalies are not good markers for
intrauterine risk factors specific to MS or that the effect
is too small to observe, given that only a small propor-
tion of anomalies are attributed solely to environmental
factors.
Our study does have limitations. Maternal recall of
congenital anomalies is likely influenced by the time
elapsed from the child’s birth and by the severity of the
condition and may not be as reliable as clinical records.
For example, a mother would more likely recall a conge-
nital anomaly needing medical intervention (e.g. cleft lip
or palate, talipes) than one that may not (e.g. minor car-
diac septal defect, spina bifida occulta). Conversely, a
mother may over-report minor afflictions as congenital
anomalies or they may report anomalies not detected at
birth. The latter would help to explain the relatively high
rate of anomalies observed compared to expected rates.
As part of the CCPGSMS to date, we did not ask specifi-
cally for information on the type and severity of the con-
genital abnormality, which maybe important for MS risk.
We also did not ask about the maternal history of fatal
congenital abnormalities in previous pregnancies; this
information would be missing from the family history
especially if an affected pregnancy resulted in a termina-
tion, miscarriage, stillbirth, or perinatal death. We antici-
pate conducting a more focused questionnaire interview
in the future as part of the ongoing CCPGSMS.
Conclusions
The maternal effect in MS is substantial. Risk for MS in
maternal half-siblings compared with the risk for full
siblings does not differ significantly indicating that
maternal effects might even be the major component of
familial aggregation of the disease [4]. Our data suggests
that congenital anomalies are not more prevalent among
those who develop MS and seems to reduce the likeli-
hood that there is a strong association between risk fac-
tors common to MS and congenital anomalies. However
our study is a preliminary investigation as we did not
have detailed data on congenital anomalies or maternal
birth history. Further investigations are needed to
explain the mechanisms underlying the increased MS
risk conferred maternally.
Compenting interests
The authors declare that they have no competing interests.
Authors’ contributions
GCE and ADS conceived and designed the experiments. SVR, CG, MC, DAD,
SMO, IMY, GCE and ADS analyzed the data and wrote the paper. All authors
read and approved the final manuscript.
Acknowledgements
This study was funded by the Multiple Sclerosis Society of Canada Scientific
Research Foundation. The authors would like to thank all patients who
generously participated in this study and physicians constituting the
Canadian Collaborative Group: CCPGSMS: Vancouver, BC (A Traboulsee V
Table 1 Clinical and demographic details of MS index
cases and controls
MS Index Cases Spousal Controls
n 7063 2655
mean age in years (SD) 50.2 (10.1) 52.3 (9.6)
n (females) 5319 807
n (males) 1744 1848
sex ratio (f:m) 3:1 0.4:1
% relapsing remitting MS 82.3 /
SD = standard deviation, (f:m) = female to male sex ratio
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